Invasive Pneumococcal Disease: Concerning Trends in Serotype 19A Notifications in New Zealand

Andrew Anglemyer; Andrea McNeill; Kara DuBray; Gerard J B Sonder; Tony Walls

doi:10.1093/cid/ciab766

Invasive Pneumococcal Disease: Concerning Trends in Serotype 19A Notifications in New Zealand

Clin Infect Dis. 2022 May 30;74(10):1859-1861. doi: 10.1093/cid/ciab766.

Authors

Andrew Anglemyer^{1

2}, Andrea McNeill¹, Kara DuBray³, Gerard J B Sonder^{1

4}, Tony Walls⁵

Affiliations

¹ Health Intelligence Team, Institute of Environmental Science and Research, Wellington, New Zealand.
² Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
³ Department of Paediatrics, Dunedin Hospital, Dunedin, New Zealand.
⁴ Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
⁵ Department of Paediatrics, University of Otago, Christchurch, New Zealand.

PMID: 34480534
DOI: 10.1093/cid/ciab766

Abstract

New Zealand (NZ) is one of few countries to shift from PCV13 to PCV10. The number of serotype 19A cases in young children and the proportions of isolates that are penicillin-resistant have been steadily increasing since. It is time for NZ to reconsider its choice of pneumococcal vaccine.

Keywords: antimicrobial resistance; pneumococcal conjugate vaccine; pneumococcal disease; serotypes; vaccine preventable diseases.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Child
Child, Preschool
Humans
Infant
New Zealand / epidemiology
Pneumococcal Infections* / epidemiology
Pneumococcal Infections* / prevention & control
Pneumococcal Vaccines
Serogroup
Streptococcus pneumoniae*
Vaccines, Conjugate

Substances

Pneumococcal Vaccines
Vaccines, Conjugate